Hot Investor Mandate: Western Europe-Based Firm Invests Up to $10M in Life Sciences Including Drug Discovery and Enabling Technologies

4 Nov

This Western Europe-based investment firm has been active for over two decades and manages multi-billion in assets under management. The firm takes a sector-agnostic approach, investing across a broad spectrum including enterprise software, fintech, consumer technologies, deeptech, and life sciences. 

Typical equity investments range from $1 million to $10 million, and the firm expects to make several new investments annually. While companies must maintain a local operational presence in the firm’s home country, they may also have international footprints. 

In the life sciences and biotech space, the firm adopts a wide-angle lens, looking for companies developing drug discovery platforms, synthetic biology innovations, and enabling research technologies.  

The firm is open to investing in pre-revenue companies, and is supportive of both emerging and experienced founding teams. It frequently invests at the early growth stage, often in syndicate with other institutional investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

ApexBrasil and ABIQUIFI Deepen Strategic Alliance with Life Science Nation to Globalize Brazil’s Life Science Ecosystem and Leveraging the RESI JPM January Event 

28 Oct

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

São Paulo – Boston | October 2025

Brazil is taking a significant step toward global integration in the life sciences. Last week, ApexBrasil (the Brazilian Trade and Investment Promotion Agency) and ABIQUIFI (the Brazilian Association of Pharmaceutical Inputs Industry) hosted Life Science Nation (LSN) and Ganesha Labs in São Paulo for a week of meetings, workshops, and strategic dialogues with key stakeholders from across the national innovation and investment landscape. 

The visit culminated during the Corporate Venture in Brasil 2025 Conference, held in São Paulo and co-hosted by ApexBrasil, which gathered leading investors, corporate venture leaders, development agencies, and innovation stakeholders to strengthen Brazil’s position in the global market. 

At the conference, LSN’s CEO, Dennis Ford, delivered a masterclass on running global fundraising campaigns and building two-way innovation bridges between regional science and global capital. This was followed by a panel discussion, “Where Brazil Is and Where We Should Aim Towards,” featuring KX Ventures, IKJ, Sebrae, Ganesha Labs, and Life Science Nation, and moderated by Marcos Valadares of ABIQUIFI. 

Over several days surrounding the conference, ApexBrasil and ABIQUIFI facilitated a series of high-level introductions that connected LSN and Ganesha Labs with leaders from accelerators, investment groups, and research institutions across Brazil. These discussions focused on aligning Brazil’s growing innovation infrastructure with global commercialization frameworks and investor networks. 

The São Paulo visit capped two years of collaboration between the organizations, during which ApexBrasil and ABIQUIFI have sent multiple cohorts of Brazilian life-science companies to LSN’s Redefining Every Stage of Investment JPM events and LSN Labs training programs. 

Together, they have provided Brazilian entrepreneurs with a structured path to international investors and licensing partners, and a deeper understanding of how to prepare and execute a global fundraising campaign. 

This ongoing collaboration is laying the groundwork for Brazil to become a formal anchor node in the LSN Global Partnering Ecosystem. This worldwide network links regional innovation hubs to global capital and corporate partners. Through continued coordination, the parties aim to establish a lasting two-way innovation bridge between Brazil and LSN’s international ecosystem, enabling Brazilian technologies to access global markets while channeling international investors and strategic partners into the country’s rapidly expanding life-science sector. 

According to Dennis Ford, Founder and CEO of Life Science Nation, 

“Brazil’s scientific depth and entrepreneurial momentum make it one of the most exciting emerging markets in life sciences. ApexBrasil and ABIQUIFI are doing exactly what global investors want to see—creating a coordinated pathway that connects local innovation with international capital and commercialization opportunities. LSN is proud to help Brazil take this next step.” 

Norberto Prestes, CEO of ABIQUIFI, emphasized the export and funding side of the bridge: 

“Brazil has a rich foundation of science and talent. Our goal is to help these innovations secure the visibility, funding, and partnerships they need to reach international markets. The collaboration with LSN provides the structure and access needed to make that happen.” 

Debora Lima of ApexBrasil highlighted the importance of bringing international investors into the Brazilian ecosystem: 

“Our mission is to connect Brazil with the world—to bring investors, partners, and collaborators to see firsthand the innovation emerging here. Working with LSN allows us to open new channels for global capital to engage directly with Brazilian startups and research institutions.” 

About Life Science Nation

Life Science Nation (LSN) is a global matching and partnering engine that connects early-stage life-science companies with investors and licensing partners through its integrated ecosystem—including the LSN Investor & Licensing Partner Database, the RESI Conference Series, and LSN Labs Accelerator. LSN has supported more than 400 companies in raising over $5 billion in verified funding worldwide.

About ApexBrasil

ApexBrasil promotes Brazilian products and services abroad and attracts foreign investment to strategic sectors of the Brazilian economy, strengthening national competitiveness and international presence.

About ABIQUIFI

ABIQUIFI represents the Brazilian Pharmaceutical Inputs Industry, advancing innovation, quality, and competitiveness across the national health and life-sciences sector.

Registration now open:

  • RESI London 2025 (Dec. 4, 8&9) – [Register]
  • RESI JPM 2026 (Jan.12-14, 19&20)– [Register]
  • RESI Europe 2026 (March 23-25) – [Register]

Tags: , , , , , , , , , , ,

RESI London 2025: An International Hub for Connections 

28 Oct

By Greg Mannix, VP, EMEA Business Development, LSN

The Redefining Every Stage of Investment (RESI) Conference is coming back to London on December 4th — and it’s shaping up to be bigger and better than ever. After a successful debut in 2024, RESI London returns to unite global investors, strategic partners, and early-stage innovators across biotech, medtech, diagnostics, and digital health. 

In today’s challenging funding landscape, breaking out of your regional bubble to build global relationships is essential. That’s exactly what RESI delivers — a trusted international platform where meaningful connections spark real partnerships and deals. 

With 54 conferences held across three continents since 2012, RESI has become a cornerstone of the global life science community, helping startups find the right investors, and investors find their next breakthrough. 

This December, RESI London will welcome international Tech Hubs and Regional Organizations collaborating through startup cohorts, promotional activities, and partner initiatives. 

We’re excited to welcome cohorts from:

  • Ontario (Canada)
  • CEIN Navarra (Spain) 
  • OneNucleus (UK) 

And we’re grateful for the ongoing collaboration of our global partners, including:
BioPartner UK, O2h (UK), Genopole, Lyonbiopole & Eurasanté (France), Life Science Zurich BP (Switzerland), BioM & BioRN (Germany), Biocat & Asebio (Spain), BioIndustry Park (Italy), PBio (Portugal), Business Regions Gotheborg/Skane (Sweden) — and many more. 

Join us in London on December 4th to connect with the global life science ecosystem and take your innovation to the next level. There is still time to pitch in the Innovator’s Pitch Challenge APPLY HERE 

90 companies have documented raising $1.29 B from connections started at RESI. Read More. 

Register for RESI London Appy to Pitch at RESI London

Tags: , , , ,

Kobe Biomedical Innovation Cluster (KBIC) Joins RESI JPM 2026 as Gold Sponsor

28 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is proud to announce that the Kobe Biomedical Innovation Cluster (KBIC) will serve as a sponsor for RESI JPM 2026, continuing its mission to promote innovation, entrepreneurship, and global collaboration in life sciences. 

As part of this sponsorship, KBIC will host the Kansai Life Sciences Accelerator Program (KLSAP) 2025 Demo Day at RESI JPM 2026 on Tuesday, January 13, 12:00 – 2:00pm PT at the Marriott Marquis San Francisco. The Demo Day will feature 3 startups that are part of the KLSAP 2025 Cohort as well as other member companies of KBIC, to be announced as the event approaches. This initiative will provide participating companies with global exposure, strategic investor connections, and the opportunity to pitch to an international audience of early-stage investors and strategic partners across life science and healthcare sectors.

Interested in joining and receiving updates on the KLSAP 2025 Demo Day? Please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.  

Introduction of Kobe Biomedical Innovation Cluster (KBIC)
Located in the heart of Kobe, Japan, the Kobe Biomedical Innovation Cluster is one of the nation’s leading ecosystems dedicated to the advancement of biomedical research and commercialization. With more than 340 organizations, including research institutes, hospitals, and life science companies, KBIC plays a vital role in bridging academia, government, and industry to accelerate innovation and improve global health outcomes. 

By partnering with RESI JPM 2026, KBIC aims to strengthen international collaboration and support Japanese startups seeking to expand their networks and raise global awareness for their technologies. Through this continued engagement, KBIC and LSN will work together help founders access global capital and strategic resources to advance from concept to commercialization. 

About Kansai Life Sciences Accelerator Program (KLSAP)
Powered by KBIC, the Kansai Life Sciences Accelerator Program (KLSAP) supports early-stage life science and healthcare startups in the Kansai region through tailored mentorship, commercialization guidance, and access to global investor networks. 

The 2025 KLSAP Cohort will participate in RESI JPM 2026 to present their innovations to a diverse investor audience, gain valuable feedback, and establish partnerships that can help drive their technologies toward global markets. The cohort’s participation exemplifies KBIC’s commitment to supporting international expansion and facilitating cross-border collaboration in life sciences. 3 companies have been selected for this year’s KLSAP Cohort, with descriptions of each company added below:

C-Biomex
Founded in 2017, C-Biomex is a bio-venture dedicated to advancing novel theranostics using its proprietary peptide discovery platform, CUS™. The platform enables identification of peptides with high stability and specificity through a three-step process involving a high-purity library, an innovative screening protocol that minimizes background interactions, and direct sequencing via a proprietary algorithm. C-Biomex focuses on radiopharmaceutical development, positioning itself at the intersection of diagnostics and therapeutics to accelerate peptide-based solutions for global biomedical applications.

GeneMedicine
GeneMedicine, founded in 2014 and based in Seoul, develops oncolytic viruses engineered to selectively replicate in and kill cancer cells while stimulating an anti-tumor immune response. Its GM-oAd platform is designed for systemic delivery of oncolytic adenoviruses with enhanced tumor specificity, immune activation, and ability to overcome physical tumor barriers. In addition to its therapeutic pipeline, GeneMedicine is expanding into CDMO services and novel drug-delivery systems, building a sustainable and diversified business model.

iXgene
iXgene is a Japanese life sciences company focused on developing therapies for intractable diseases using genome editing and induced pluripotent stem (iPS) cell technology. Its proprietary platform combines advanced genome editing tools, such as CRISPR, with iPS-derived therapeutics targeting indications including malignant brain tumors and brain injury. iXgene collaborates with academic institutions and pharmaceutical partners to translate next-generation regenerative and gene therapies into the clinic, aiming to address high-unmet-need central nervous system diseases. 

LSN and KBIC invites all investors, industry leaders, and innovators to meet the KLSAP 2025 Cohort at RESI JPM 2026. Together, they will continue to advance global innovation and foster meaningful connections across the life sciences ecosystem. 

Register for RESI JPM

Tags: , , , , , , , , , ,

Winning Innovation: IsoTech on Blood Pressure Therapy and Pitching at RESI 

28 Oct

By Caitlin Dolegowski, Marketing Manager, LSN

IsoTech Ltd, the first-place winner of the Innovator’s Pitch Challenge at RESI Boston, is tackling orthostatic hypotension with ISO-101, a wearable therapeutic device that stabilizes blood pressure on standing to help older adults avoid dizziness and falls. In this interview with Dr. Lochlainn Connolly, he discusses their proof-of-concept results, progress toward design-for-manufacture and pilot build, and their experience pitching at RESI Boston. 

The Innovator’s Pitch Challenge is now open for both RESI London and RESI JPM, with the application deadline extended to November 12. 

Appy to Pitch at RESI London Appy to Pitch at RESI JPM

Hot Investor Mandate: Western Europe-Based VC Firm Focuses on Medtech and Digital Health Investments Across the Globe

28 Oct

Founded in 2021, an early-stage venture capital firm based in Western Europe invests in multiple verticals. Within life science and healthcare, the firm focuses on medtech and digital health. The sweet point for the firm is pre-seed. Initial investment is typically around €600K, with the potential for follow-on investment of another €600K Euro. The firm is open to opportunities globally with no geographical restrictions. While the firm is open to both leading and co-investing in rounds, the firm would prefer if there is a lead investor in place. 
 
Within life science and healthcare, the firm is focused on medtech and digital health, and is opportunistic in subsectors and indications. Some areas of interest are: surgical devices and cardiovascular diseases. For the stage of development, the firm is open to investing in the preclinical stage, but would prefer companies that have prototypes. 
 
There is no specific requirement for the company’s management team. The firm is interested in working with experienced entrepreneurs. The firm is an active investor and will consider observer seats on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Angel Syndicate Targets Investments Into Life Science Tools, Software, and Platform Technologies Across Pre-Seed to Series A

28 Oct

An angel syndicate is focused on life science tools and biotech infrastructure. The firm has a concentrated investment strategy targeting U.S.-based companies from the Pre-Seed to Series A stages. The firm’s investor base includes a select group of limited partners, about half of whom are active operators within the life science tools sector. The firm can co-invest but prefers to lead investments, with typical check sizes ranging from $160K to $2M. The firm brings deep domain expertise in life sciences and works closely with founders to build companies, pairing them with strategic capital. The firm is thesis-driven and leverages its extensive operator network, commercial reach, and M&A experience to accelerate company growth and strategy. The firm supports all aspects of business development, from financial modeling and strategic planning to connecting founders with key industry stakeholders within the life sciences ecosystem. 

The firm exclusively targets life science tools, software, biotech infrastructure, and platform technologies that typically include a consumable component. The firm does not invest in therapeutics, diagnostics, digital health, or any business requiring FDA clearance. The firm is open to all development stages and all classes of tools, software, and platform technologies. 

The firm only works with companies whose founders and teams are fully dedicated to their ventures. The firm generally prefers to take a board seat if it leads the investment round and if doing so aligns with the company’s stage of development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →